John F R Robertson

Summary

Affiliation: University of Nottingham
Country: UK

Publications

  1. doi request reprint Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study
    John F R Robertson
    Division of Breast Surgery, Graduate Entry Medicine and Health School GEMS, University of Nottingham, Royal Derby Hospital, Uttoxeter Road, Derby, DE22 3DT, UK
    Breast Cancer Res Treat 136:503-11. 2012
  2. pmc Technical validation of an autoantibody test for lung cancer
    A Murray
    Oncimmune Ltd, UK
    Ann Oncol 21:1687-93. 2010
  3. pmc Clinical validation of an autoantibody test for lung cancer
    P Boyle
    International Prevention Research Institute, Lyon, France
    Ann Oncol 22:383-9. 2011
  4. doi request reprint Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
    John Fr Robertson
    Royal Derby Hospital, Derby, UK
    Lancet Oncol 14:228-35. 2013
  5. pmc erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines
    Janice M Knowlden
    Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, CF10 3NB, UK
    Breast Cancer Res 13:R93. 2011
  6. pmc Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells
    Iain R Hutcheson
    Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3XF, UK
    Breast Cancer Res 9:R50. 2007
  7. ncbi request reprint The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer
    J F Robertson
    Professional Unit of Surgery, City Hospital, Nottingham, UK
    Eur J Cancer 35:47-53. 1999
  8. ncbi request reprint Faslodex (ICI 182, 780), a novel estrogen receptor downregulator--future possibilities in breast cancer
    J F Robertson
    Nottingham City Hospital, Hucknall Road, NG5 1PB, Nottingham, UK
    J Steroid Biochem Mol Biol 79:209-12. 2001
  9. ncbi request reprint Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer
    J F Robertson
    Professorial Unit of Surgery, City Hospital, Nottingham, U K
    Eur J Cancer 35:214-8. 1999
  10. ncbi request reprint Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer
    J F Robertson
    Department of Surgery, City Hospital, Nottingham, UK
    Breast Cancer Res Treat 58:157-62. 1999

Detail Information

Publications87

  1. doi request reprint Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study
    John F R Robertson
    Division of Breast Surgery, Graduate Entry Medicine and Health School GEMS, University of Nottingham, Royal Derby Hospital, Uttoxeter Road, Derby, DE22 3DT, UK
    Breast Cancer Res Treat 136:503-11. 2012
    ....
  2. pmc Technical validation of an autoantibody test for lung cancer
    A Murray
    Oncimmune Ltd, UK
    Ann Oncol 21:1687-93. 2010
    ..Precision, linearity, assay reproducibility and antigen batch reproducibility were all assessed...
  3. pmc Clinical validation of an autoantibody test for lung cancer
    P Boyle
    International Prevention Research Institute, Lyon, France
    Ann Oncol 22:383-9. 2011
    ..We report the clinical validation of an autoantibody panel in newly diagnosed patients with lung cancer (LC)...
  4. doi request reprint Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
    John Fr Robertson
    Royal Derby Hospital, Derby, UK
    Lancet Oncol 14:228-35. 2013
    ..Ganitumab is a monoclonal IgG1 antibody that blocks IGF-1R. We tested the efficacy and safety of adding ganitumab to endocrine treatment for patients with hormone-receptor-positive breast cancer...
  5. pmc erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines
    Janice M Knowlden
    Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, CF10 3NB, UK
    Breast Cancer Res 13:R93. 2011
    ..In this study, we examined whether IRS-1 also associates with another erbB receptor family member, erbB3, and what impact this might have on IGF-IR signalling in three ER+ breast cancer cell lines...
  6. pmc Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells
    Iain R Hutcheson
    Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3XF, UK
    Breast Cancer Res 9:R50. 2007
    ..In the present study we have examined whether HRG signalling can circumvent EGFR blockade in an EGFR-positive tamoxifen-resistant MCF-7 (Tam-R) breast cancer cell line...
  7. ncbi request reprint The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer
    J F Robertson
    Professional Unit of Surgery, City Hospital, Nottingham, UK
    Eur J Cancer 35:47-53. 1999
    ..The results using CA15-3 and CEA were similar but 12% less patients were assessable. CA15-3 and CEA (with and without ESR) provide an objective method to guide therapy in patients with metastatic breast cancer...
  8. ncbi request reprint Faslodex (ICI 182, 780), a novel estrogen receptor downregulator--future possibilities in breast cancer
    J F Robertson
    Nottingham City Hospital, Hucknall Road, NG5 1PB, Nottingham, UK
    J Steroid Biochem Mol Biol 79:209-12. 2001
    ....
  9. ncbi request reprint Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer
    J F Robertson
    Professorial Unit of Surgery, City Hospital, Nottingham, U K
    Eur J Cancer 35:214-8. 1999
    ..Transient liver function test abnormalities developed in a number of patients, mainly during the first 6 weeks of treatment. In conclusion Onapristone can induce tumour responses in human breast cancer...
  10. ncbi request reprint Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer
    J F Robertson
    Department of Surgery, City Hospital, Nottingham, UK
    Breast Cancer Res Treat 58:157-62. 1999
    ..This paper reports on the clinical relevance of durable static disease (SD) (> or = 24 weeks) in breast cancer patients treated with the aromatase inhibitor anastrozole...
  11. ncbi request reprint Effects of fulvestrant 250mg in premenopausal women with oestrogen receptor-positive primary breast cancer
    J F R Robertson
    Unit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK
    Eur J Cancer 43:64-70. 2007
    ..These findings suggest that a higher fulvestrant dose may be required in this patient population. Further clinical trials are necessary to evaluate the efficacy of fulvestrant in premenopausal women...
  12. ncbi request reprint Fulvestrant (Faslodex) -- how to make a good drug better
    John F R Robertson
    Nottingham City Hospital, Hucknall Road, Nottingham, UK
    Oncologist 12:774-84. 2007
    ..Meanwhile, fulvestrant (250 mg/month) remains a valuable additional endocrine treatment for postmenopausal women with HR(+) ABC recurring or progressing on antiestrogen therapy...
  13. doi request reprint Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study
    John F R Robertson
    Division of Breast Surgery, University of Nottingham, Nottingham City Hospital, Hucknall Rd, Nottingham, NG5 1PB, United Kingdom
    J Clin Oncol 27:4530-5. 2009
    ....
  14. ncbi request reprint Activity of fulvestrant in HER2-overexpressing advanced breast cancer
    J F R Robertson
    University of Nottingham, Nottingham City Hospital, Nottingham, UK
    Ann Oncol 21:1246-53. 2010
    ..This retrospective study evaluated response to fulvestrant treatment among HER2-positive patients with advanced breast cancer (ABC)...
  15. ncbi request reprint Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective
    John F R Robertson
    Department of Surgery, City Hospital, Hucknall Road, Nottingham NG5 1PB, UK
    Cancer Treat Rev 30:695-706. 2004
    ..Pure antioestrogens such as the ER antagonist fulvestrant provide opportunities for therapeutic sequencing with tamoxifen and AIs and offer exciting possibilities for the future treatment of breast cancer...
  16. ncbi request reprint Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant
    J F R Robertson
    Unit of Surgery, City Hospital, NG5 1PB, Nottingham, UK
    Breast Cancer Res Treat 92:169-74. 2005
    ..Results from this questionnaire-based study suggest that postmenopausal women with advanced breast cancer who respond to first-line fulvestrant or tamoxifen retain sensitivity to subsequent endocrine therapy...
  17. ncbi request reprint The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women
    J F R Robertson
    Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK
    Eur J Cancer 39:861-9. 2003
    ..Endocrine therapy with goserelin or goserelin plus tamoxifen should now be considered a treatment option in the management of premenopausal women with ER +ve early breast cancer...
  18. ncbi request reprint Pharmacokinetics of a single dose of fulvestrant prolonged-release intramuscular injection in postmenopausal women awaiting surgery for primary breast cancer
    John F R Robertson
    Nottingham City Hospital, Nottingham, United Kingdom
    Clin Ther 25:1440-52. 2003
    ....
  19. ncbi request reprint Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials
    John F R Robertson
    Department of Surgery, Nottingham City Hospital, Nottingham, United Kingdom
    Cancer 98:229-38. 2003
    ....
  20. pmc Fulvestrant: pharmacokinetics and pharmacology
    J F R Robertson
    Unit of Surgery, City Hospital, Nottingham NG5 1PB, UK
    Br J Cancer 90:S7-10. 2004
    ....
  21. ncbi request reprint Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant ('Faslodex') in postmenopausal women with advanced breast cancer
    John F R Robertson
    City Hospital, Hucknall Road, Nottingham, UK
    Cancer Chemother Pharmacol 52:346-8. 2003
    ..To compare the pharmacokinetics of two different dosing methods of fulvestrant ('Faslodex'), an estrogen receptor antagonist with no known agonist activity, for the treatment of advanced breast cancer...
  22. ncbi request reprint Endocrine treatment options for advanced breast cancer--the role of fulvestrant
    J F R Robertson
    Unit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK
    Eur J Cancer 41:346-56. 2005
    ....
  23. ncbi request reprint Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes
    Emad A Rakha
    Department of Histopathology, School of Molecular Medical Sciences, Nottingham University Hospitals NHS Trust, University of Nottingham, Nottingham, UK
    Eur J Cancer 44:73-83. 2008
    ..It is less common than invasive ductal carcinoma (IDC) and few large studies have addressed its biologic characteristics and behaviour with respect to long-term clinical outcome and response to adjuvant therapy...
  24. ncbi request reprint Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype
    Emad A Rakha
    Department of Histopathology and Surgery, School of Molecular Medical Sciences, Nottingham University Hospitals National Health Service Trust and University of Nottingham, Nottingham, United Kingdom
    J Clin Oncol 25:4772-8. 2007
    ..It is usually easier to decide treatment strategies in cases of double-positive/-negative phenotypes than in single-positive tumors...
  25. pmc Application of a high throughput method of biomarker discovery to improvement of the EarlyCDT(®)-Lung Test
    Isabel K Macdonald
    Oncimmune Ltd, Nottingham City Hospital, Nottingham, United Kingdom
    PLoS ONE 7:e51002. 2012
    ..The aim of this study was to demonstrate the successful clinical application of this strategy to add to the EarlyCDT-Lung panel in order to improve its sensitivity and specificity (and hence positive predictive value, (PPV))...
  26. ncbi request reprint Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer
    John F R Robertson
    Nottingham City Hospital, Nottingham, UK
    Clin Pharmacokinet 43:529-38. 2004
    ..To characterise the pharmacokinetics of a long-acting formulation of fulvestrant following intramuscular administration of single and multiple doses...
  27. pmc Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients
    Kristjan S Asgeirsson
    Division of Breast Surgery, University of Nottingham, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK
    Breast Cancer Res 9:R75. 2007
    ..The clinical relevance of this has not been fully established...
  28. pmc Successful management of elderly breast cancer patients treated without radiotherapy
    Kalliope Valassiadou
    Division of Breast Surgery, University of Nottingham, Nottingham, UK
    World J Surg Oncol 5:62. 2007
    ..The addition of RT to surgery might constitute an imposition to such patients due to age-related factors. The aim of this study was to assess the efficacy of BCS without adjuvant RT in this group of patients...
  29. pmc Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy
    S G Archer
    Professional Unit of Surgery, Nottingham City Hospital, UK
    Br J Cancer 72:1259-66. 1995
    ....
  30. ncbi request reprint Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer
    J F Robertson
    Department of Surgery, Nottingham City Hospital, Nottingham, United Kingdom
    Cancer Res 61:6739-46. 2001
    ..Reductions in tumor cell proliferative activity (as indicated by Ki67LI) show that ICI 182,780 is likely to have antitumor activity in the clinical setting...
  31. ncbi request reprint Current role of endocrine therapy in the management of breast cancer
    John F R Robertson
    Professorial Unit of Surgery, City Hospital, Nottingham NG5 1PB, UK
    Breast Cancer 9:276-81. 2002
  32. ncbi request reprint Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer
    F S Kenny
    Professorial Unit of Surgery, Nottingham City Hospital, UK
    Breast Cancer Res Treat 65:135-44. 2001
    ....
  33. pmc EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays
    Caroline J Chapman
    Centre of Excellence for Autoimmunity in Cancer, The University of Nottingham, Nottingham, UK
    Tumour Biol 33:1319-26. 2012
    ..The change from a six- to a seven-AAb assay can improve the specificity of the test and would result in a PPV of 1 in 8 and an overall accuracy of 92 %...
  34. pmc The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast
    Zsolt Hodi
    Departments of Histopathology and Surgery, Nottingham City Hospital, UK
    J Clin Pathol 60:299-302. 2007
    ..To assess the reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast. Previous studies have mostly been small, with a range of agreement from 62% to 100%...
  35. ncbi request reprint Locally advanced primary breast cancer: medium-term results of a randomised trial of multimodal therapy versus initial hormone therapy
    S M Tan
    Department of Surgery, City Hospital, Nottingham, UK
    Eur J Cancer 37:2331-8. 2001
    ..Thus, initial hormone therapy may be a reasonable option for managing locally advanced primary breast cancer, especially for oestrogen receptor-positive tumours...
  36. pmc Development and validation of a high throughput system for discovery of antigens for autoantibody detection
    Isabel K Macdonald
    Oncimmune Ltd, Nottingham City Hospital, Nottingham, United Kingdom
    PLoS ONE 7:e40759. 2012
    ....
  37. pmc Clinical relevance of "withdrawal therapy" as a form of hormonal manipulation for breast cancer
    Amit Agrawal
    Division of Breast Surgery, GEM School, University of Nottingham, Royal Derby Hospital, Derby DE22 3NE, UK
    World J Surg Oncol 9:101. 2011
    ..However, evidence is scarce when this is extrapolated into clinical context. We report our experience to verify the clinical relevance of "withdrawal therapy"...
  38. doi request reprint EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer
    Stephen Lam
    Department of Pulmonary Medicine, British Columbia Cancer Agency, Vancouver, Canada
    Cancer Prev Res (Phila) 4:1126-34. 2011
    ..These studies confirm the value of an autoantibody assay, EarlyCDT-Lung, as an aid to detecting lung cancer in patients at high risk of the disease...
  39. doi request reprint Immunobiomarkers in small cell lung cancer: potential early cancer signals
    Caroline J Chapman
    Division of Surgery, University of Nottingham, Nottingham, United Kingdom
    Clin Cancer Res 17:1474-80. 2011
    ....
  40. ncbi request reprint High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses
    Dalia M Abd El-Rehim
    Department of Histopathology, The Breast Unit, Nottingham City Hospital NHS Trust and University of Nottingham, Nottingham, United Kingdom
    Int J Cancer 116:340-50. 2005
    ..These observations could form the basis of revision of existing traditional classification systems for breast cancer...
  41. ncbi request reprint Selective use of post-mastectomy flap irradiation in high-risk breast cancer patients
    Kristjan S Asgeirsson
    The Nottingham Breast Institute, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK
    Breast 14:298-303. 2005
    ..The chest wall recurrence rate was 2.7% in those treated with radiotherapy. A low rate of local recurrence has been achieved with selective use of mastectomy flap radiotherapy...
  42. ncbi request reprint Fulvestrant
    Kwok Leung Cheung
    Professorial Unit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK
    Expert Opin Investig Drugs 11:303-8. 2002
    ..With the role of tamoxifen as the gold standard of first-line therapy being challenged by the third generation aromatase inhibitors, direct comparison of the latter with fulvestrant in the first-line setting may also be worthwhile...
  43. doi request reprint Incidence of intramammary nodes in completion mastectomy specimens after axillary node sampling: implications for breast conserving surgery
    R S Rampaul
    Nottingham Breast Institute, Nottingham University Hospital, City Hospital Campus, Hucknall Road, Nottingham NG5 1PB, UK
    Breast 17:195-8. 2008
    ..This study aims to assess the incidence of such nodes in completion mastectomy specimens in women who have had previous breast conserving surgery and ANS...
  44. ncbi request reprint Autoantibodies in lung cancer: possibilities for early detection and subsequent cure
    C J Chapman
    Division of Breast Surgery, The University of Nottingham, Nottingham NG5 1PB, UK
    Thorax 63:228-33. 2008
    ..Autoantibodies have been shown to be present in the circulation of people with various forms of solid tumour before cancer-associated antigens can be detected, and these molecules can be measured up to 5 years before symptomatic disease...
  45. ncbi request reprint The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy
    K L Cheung
    Department of Surgery, City Hospital, Nottingham, United Kingdom
    Breast Cancer Res Treat 67:273-8. 2001
    ..5 months. Biochemical assessment by blood tumour markers is useful in patients with metastatic breast cancer unassessable for response to systemic therapy. These findings need to be confirmed in a larger patient series...
  46. ncbi request reprint Evaluation of the IMMULITE BR-MA and CEA assays and comparison with immunoradiometric assays for CA15-3 and CEA in breast cancer
    A Murray
    Department of Pharmaceutical Sciences, University of Nottingham, University Park, UK
    Anticancer Res 17:1945-9. 1997
    ..We conclude that the IMMULITE Automated Immunoassay Analyzer is of value in the routine surveillance of tumour marker levels...
  47. pmc Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer
    J F Robertson
    City Hospital, Nottingham, UK
    Br J Cancer 65:727-30. 1992
    ..The predictive power of these assay for progression of disease appears slightly better for the ER-ICA...
  48. ncbi request reprint Effect of dietary GLA+/-tamoxifen on the growth, ER expression and fatty acid profile of ER positive human breast cancer xenografts
    F S Kenny
    Professorial Unit of Surgery, City Hospital, Nottingham, United Kingdom
    Int J Cancer 92:342-7. 2001
    ..The effects of GLA on ER function and the possibility of synergistic inhibitory action of GLA with tamoxifen via enhanced down-regulation of the ER pathway require further investigation...
  49. ncbi request reprint Clinical value of epidermal growth factor receptor expression in primary breast cancer
    R S Rampaul
    Nottingham Breast Institute, University of Nottingham, Nottingham City Hospital, NHS Trust, Nottingham, UK
    Adv Anat Pathol 12:271-3. 2005
    ..The impetus to standardize such studies is much needed as there are now several tyrosine kinase inhibitors directed against the EGF receptor and phase II trials are showing significant promise...
  50. ncbi request reprint Selection of primary breast cancer patients for adjuvant endocrine therapy--is oestrogen receptor alone adequate?
    K L Cheung
    Professorial Unit of Surgery, City Hospital, Nottingham, UK
    Breast Cancer Res Treat 65:155-62. 2001
    ..Further studies to elucidate other possible factors are warranted to refine the use of endocrine therapy, especially in the adjuvant setting when no indication of response is available...
  51. pmc ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data
    J F Robertson
    Department of Surgery, City Hospital Nottingham, UK
    Br J Cancer 85:11-4. 2001
    ..As such, ICI 182,780 will provide a valuable addition to the armamentarium for the treatment of advanced breast cancer...
  52. ncbi request reprint The role of blood tumor marker measurement (using a biochemical index score and c-erbB2) in directing chemotherapy in metastatic breast cancer
    K L Cheung
    Department of Surgery, City Hospital, Nottingham, UK
    Int J Biol Markers 15:203-9. 2000
    ..003). Among the patients with positive tissue staining, sequential changes in serum c-erbB2 completely paralleled initial response...
  53. ncbi request reprint Metastatic carcinoma of the breast with tubular features: differences compared with metastatic ductal carcinoma of no specific type
    L J Hamilton
    Nottingham Breast Institute, Nottingham City Hospital, Nottingham, UK
    Clin Oncol (R Coll Radiol) 16:119-24. 2004
    ....
  54. ncbi request reprint New calmodulin antagonists inhibit in vitro growth of human breast cancer cell lines independent of their estrogen receptor status
    E Jacobs
    Department of Surgery, City Hospital, Nottingham, UK
    Anticancer Drugs 11:63-8. 2000
    ..Calmodulin antagonists effectively reduced cell growth of both ER-positive and -negative human breast cancer cell lines in vitro. Calmodulin antagonists represent a novel therapeutic approach requiring further investigation...
  55. ncbi request reprint Use of autoantibodies in breast cancer screening and diagnosis
    Sarah J Storr
    Tumor Immunology Group, University of Nottingham, Division of Breast Surgery, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK
    Expert Rev Anticancer Ther 6:1215-23. 2006
    ..In addition, autoantibody responses in breast cancer have been correlated with patient survival and their response to treatment...
  56. pmc Bony metastases from breast cancer - a study of foetal antigen 2 as a blood tumour marker
    Kwok Leung Cheung
    Division of Breast Surgery, University of Nottingham, Nottingham, UK
    World J Surg Oncol 8:38. 2010
    ..Serum concentrations of FA-2 appeared to be elevated in a number of disorders of bone metabolism. This paper is the first report of its role as a marker of bone metabolism in metastatic breast cancer...
  57. pmc Early-onset breast cancer--histopathological and prognostic considerations
    J Kollias
    Nottingham City Hospital, UK
    Br J Cancer 75:1318-23. 1997
    ..The association of young age at diagnosis with a worse prognosis in this series is explained by a higher proportion of poorly differentiated cancers; age itself had no influence on the prognosis of the individual...
  58. pmc Anti-gonadotrophin releasing hormone antibodies inhibit the growth of MCF7 human breast cancer xenografts
    E Jacobs
    Department of Surgery, University Hospital, Nottingham, UK
    Br J Cancer 80:352-9. 1999
    ..9% and 53% respectively of levels in controls, both P = 0.04). It is postulated that one of the mechanisms by which anti-GnRH antibody treatment inhibits tumour growth is indirectly, by reducing serum oestrogen levels...
  59. pmc E-cadherin as a prognostic indicator in primary breast cancer
    C Parker
    Department of Histopathology, University of Nottingham, City Hospital, Hucknall Road, Nottingham NHS Trust
    Br J Cancer 85:1958-63. 2001
    ..Thus E-CD expression in human breast cancer appears to have minimal prognostic value, but may have a role as a phenotypic marker...
  60. ncbi request reprint C-erbB2 expression predicts response to preoperative chemotherapy for locally advanced breast cancer
    P C Willsher
    Professorial Department of Surgery, City Hospital, Nottingham, U K
    Anticancer Res 18:3695-8. 1998
    ..Previous work suggests that the presence of c-erbB2 oncoprotein immunostaining and the proliferation rate of tumours, may be relevant to chemo-sensitivity in breast cancer...
  61. pmc Objective measurement of therapeutic response in breast cancer using tumour markers
    J F Robertson
    Professional Unit of Surgery, City Hospital, Nottingham, UK
    Br J Cancer 64:757-63. 1991
    ..Changes in the three markers appears to reflect the dynamics of change in tumour mass in response to systemic therapy in contrast to the UICC criteria which reflect structural change...
  62. pmc c-erbB-2 oncoprotein expression in primary and advanced breast cancer
    C Lovekin
    Department of Pathology, City Hospital, Nottingham, UK
    Br J Cancer 63:439-43. 1991
    ..In conclusion, this study demonstrates, in a large series of patients presenting to one centre, that c-erbB-2 protein expression is a prognostic indicator in patients with primary operable and advanced breast disease...
  63. ncbi request reprint Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer
    Emad A Rakha
    Department of Histopathology, The Breast Unit, Nottingham City Hospital, University of Nottingham, Nottingham, UK
    Mod Pathol 18:1295-304. 2005
    ..In conclusion, most breast carcinomas express MUC1, MUC3 and MUC4. Among the various mucins expressed in breast cancer, MUC1 and MUC3 are potential prognostic indicators, MUC1 having the strongest relationship with patient outcome...
  64. pmc C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators
    A Travis
    Department of Histopathology, City Hospital, Nottingham, UK
    Br J Cancer 74:229-33. 1996
    ..It seems, however, unlikely that c-erbB-3 protein expression will emerge as a powerful enough prognostic factor to be of value in clinical practice...
  65. pmc Potential for cost economies in guiding therapy in patients with metastatic breast cancer
    J F Robertson
    Department of Surgery, City Hospital, Nottingham, UK
    Br J Cancer 72:174-7. 1995
    ..The paper presents estimates of potential cost savings resulting from the use of serum markers in place of conventional assessment and argues that the size of these savings merits the establishment of a randomised controlled trial...
  66. pmc Failure of CA19-9 to detect asymptomatic colorectal carcinoma
    W M Thomas
    Department of Surgery, Queen s Medical Centre, Nottingham, UK
    Br J Cancer 63:975-6. 1991
    ..3% for the detection of colorectal cancer with liver metastases but only 17.6% for asymptomatic cancer. Serum CA19-9 estimation is of no value as a means of screening for asymptomatic colorectal cancer...
  67. ncbi request reprint Neuroendocrine differentiation and prognosis in breast adenocarcinoma
    A Miremadi
    Department of Histopathology, Nottingham City Hospital, Nottingham, UK
    Histopathology 40:215-22. 2002
    ..To date there are few detailed studies examining its relevance in breast carcinoma. In this study we evaluate the frequency and prognostic importance of neuroendocrine differentiation in breast adenocarcinoma...
  68. pmc Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival
    S E Pinder
    Department of Histopathology, City Hospital, Nottingham, UK
    Br J Cancer 71:146-9. 1995
    ..The results suggest that the tumour growth fraction, as assessed by the MIB1 labelling index, is an important predictor of survival...
  69. ncbi request reprint Extent of ductal carcinoma in situ within and surrounding invasive primary breast carcinoma
    N Crombie
    Department of Histopathology, City Hospital NHS Trust, Nottingham, UK
    Br J Surg 88:1324-9. 2001
    ..This effect is restricted to the volume of DCIS in the tissue surrounding the invasive lesion rather than the intratumoral component...
  70. pmc Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival
    A R Dixon
    Department of Surgery, City Hospital, Nottingham, UK
    Br J Cancer 62:868-70. 1990
    ..With the proven efficacy and minimal morbidity associated with goserelin we believe there is no current role for surgical oophorectomy in the management of premenopausal patients with advanced breast cancer...
  71. pmc Arzoxifene: the evidence for its development in the management of breast cancer
    Lee R Jackson
    Professorial Unit of Surgery, Nottingham City Hospital, Nottingham, UK
    Core Evid 2:251-8. 2008
    ..CLINICAL POTENTIAL: Despite early promise as the "ideal SERM", results from a phase III trial have relegated arzoxifene to research in breast cancer prevention and osteoporosis treatment...
  72. pmc Oestrogen receptor: a stable phenotype in breast cancer
    J F Robertson
    City Hospital, Nottingham, UK
    Br J Cancer 73:5-12. 1996
    ..Equally, if the hypothesis is true, attempts to develop laboratory models of endocrine resistance where ER-positive tumours become ER negative need to be re-evaluated...
  73. pmc Metallothionein expression in human breast cancer
    H Goulding
    Department of Histopathology, City Hospital, Nottingham, UK
    Br J Cancer 72:968-72. 1995
    ..The assessment of metallothionein expression in human breast cancer appears to provide prognostic information and may have important implications for understanding its development...
  74. ncbi request reprint Imaging of metastatic breast cancer: distribution and radiological assessment at presentation
    J P Whitlock
    City Hospital, Nottingham, UK
    Clin Oncol (R Coll Radiol) 13:181-6. 2001
    ..Therefore, of the 100 patients, 75% (95% confidence interval (CI) 65-83) had radiologically assessable disease, with 55% (95% 45-65 CI) having measurable lesions by UICC criteria...
  75. pmc Thymidine kinase in breast cancer
    J F Robertson
    City Hospital, Nottingham, UK
    Br J Cancer 62:663-7. 1990
    ..62-38.5 pmol ml-1 h-1). Serum thymidine kinase reflects stage of disease in breast cancer. Serial thymidine kinase levels in patients with systemic breast cancer reflected response to systemic therapy...
  76. pmc Therapeutic effect of the gastrin receptor antagonist, CR2093 on gastrointestinal tumour cell growth
    S A Watson
    Cancer Research Campaign Laboratories, University of Nottingham, UK
    Br J Cancer 65:879-83. 1992
    ..6 x 10(-10) M (AR42J) and 1.2 x 10(-9) M (MKN45) respectively whereas the Kd of C523 was of higher affinity (2.2 x 10(-10) M). GR antagonists may be a viable therapeutic option for gastrin receptor positive, gastro-intestinal tumours...
  77. ncbi request reprint Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials
    Anthony Howell
    Department of Medical Oncology, Cancer Research UK, Christie Hospital, Manchester, United Kingdom
    Cancer 104:236-9. 2005
    ..The authors reported the overall survival results from these studies...
  78. ncbi request reprint Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial
    Anthony Howell
    Christie Hospital and Holt Radium Institute, Manchester, UK
    J Clin Oncol 22:1605-13. 2004
    ....
  79. doi request reprint Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT
    Stephen Chia
    Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, 600 West 10 Avenue, Vancouver, BC, Canada
    J Clin Oncol 26:1664-70. 2008
    ..Because many patients subsequently experience progression or relapse, it is important to identify agents with efficacy after AI failure...
  80. ncbi request reprint An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer 95:2006-16. 2002
    ..Because these agents ultimately may be administered for periods of up to 5 years in the adjuvant setting, it is of increasing importance to assess their tolerability and pharmacologic profiles...
  81. ncbi request reprint Fulvestrant in advanced male breast cancer
    Amit Agrawal
    Breast Cancer Res Treat 101:123. 2007
  82. ncbi request reprint Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer
    Aman U Buzdar
    Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Ann Pharmacother 40:1572-83. 2006
    ..To compare the pharmacologic profile of fulvestrant with that of tamoxifen and the aromatase inhibitors with respect to the choice of treatment for advanced breast cancer (ABC)...
  83. pmc The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer
    Kathryn M Taylor
    Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Cardiff, United Kingdom
    Mol Med 13:396-406. 2007
    ..HKE4, however, did show an association with the marker of cell proliferation Ki67 the spread of breast cancer to lymph nodes...
  84. ncbi request reprint Expression of luminal and basal cytokeratins in human breast carcinoma
    Dalia M Abd El-Rehim
    Department of Histopathology, Breast Unit, Nottingham City Hospital NHS Trust and University of Nottingham, UK
    J Pathol 203:661-71. 2004
    ..These findings provide further evidence that breast cancer has distinct differentiation subclasses that have both biological and clinical relevance...
  85. doi request reprint Boost or not
    David A L Morgan
    J Clin Oncol 26:1013-4; author reply 1014. 2008